ICER said a $14,000 drug should be a fraction of the cost. Why its makers listened.

In an unusual twist, the makers of cholesterol drug Praluent are re-pricing the treatment to align with the nonprofit's recommendation. Is industry warming to ICER?

from Most popular articles from Medical Marketing and Media https://ift.tt/2DW86lk